Artificial Intelligence company BenevolentAI has bought a drug discovery and development facility at the Babraham Research Campus in Cambridge for an undisclosed sum.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
